A Nature Communications 2025 study identified mTORC1 signaling in group 2 innate lymphoid cells (ILC2s) as a central node linking neuronal cues to allergic lung inflammation. The authors used genetic perturbation and in vivo allergy models to show mTORC1 activation in ILC2s amplifies type 2 cytokine production and airway hyperreactivity. They map a neuro-immune circuit that connects neuronal inputs to metabolic reprogramming in ILC2s. ILC2s are innate immune cells that orchestrate type 2 responses; this work highlights mTORC1 as a druggable pathway and suggests metabolic inhibitors could modulate neuro-immune drivers of asthma and allergic disease.